Capital Advisors Ltd’s ARK Genomic Revolution ETF ARKG Stock Holding History

Capital Advisors Ltd’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42K	Hold	1,000	–	–	﹤0.01%	538
2026 Q1	$26K	Hold	1,000	–	–	﹤0.01%	614
2025 Q4	$29K	Hold	1,000	–	–	﹤0.01%	587
2025 Q3	$28K	Hold	1,000	–	–	﹤0.01%	579
2025 Q2	$24K	Hold	1,000	–	–	﹤0.01%	594
2025 Q1	$21K	Hold	1,000	–	–	﹤0.01%	604
2024 Q4	$24K	Sell	1,000 -1,000	-50%	-$24.6K	﹤0.01%	584
2024 Q3	$51K	Hold	2,000	–	–	0.01%	446
2024 Q2	$47K	Hold	2,000	–	–	0.01%	450
2024 Q1	$58K	Hold	2,000	–	–	0.01%	419
2023 Q4	$66K	Hold	2,000	–	–	0.01%	382
2023 Q3	$56K	Hold	2,000	–	–	0.01%	394
2023 Q2	$68K	Hold	2,000	–	–	0.01%	383
2023 Q1	$60K	Hold	2,000	–	–	0.01%	355
2022 Q4	$56K	Hold	2,000	–	–	0.01%	362
2022 Q3	$66K	Hold	2,000	–	–	0.01%	343
2022 Q2	$63K	Hold	2,000	–	–	0.01%	344
2022 Q1	$92K	Buy	+2,000	New	+$95.4K	0.02%	320

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Capital Advisors Ltd's ARKG Position: Q2 2026 in Review

Capital Advisors Ltd held its ARK Genomic Revolution ETF (ARKG) position steady in Q2 2026 at 1,000 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #538.

Capital Advisors Ltd first reported a position in ARKG in Q1 2022 and has held it in 18 quarters since. The position peaked at $92K in Q1 2022. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Capital Advisors Ltd held 1,000 shares of ARK Genomic Revolution ETF worth $42K as of Q2 2026.
Capital Advisors Ltd left its ARK Genomic Revolution ETF share count unchanged in Q2 2026.
ARK Genomic Revolution ETF made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #538 holding.
Capital Advisors Ltd first reported a position in ARK Genomic Revolution ETF in Q1 2022 and has held it in 18 quarters since.
Capital Advisors Ltd's ARK Genomic Revolution ETF position peaked at $92K in Q1 2022.
271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.